Ipsen at a glance

Innovation for

patient care

Press releases

26 January 2015

Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults

07 January 2015

Ipsen announces its corporate agenda for 2015

YOU ARE ON IPSEN'S CORPORATE WEBSITE

The corporate website is governed by the International Federation of Pharmaceutical Manufacturers & Associations code of practice.
Certain information provided on this website may not be strictly in conformity with the French regulations on advertising.

> Close